FDA Broadens Approval for Targeted Leukemia Drug in Frontline Treatment
Federal regulators have expanded the approval of the non-covalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib, marketed as Jaypirca, for adults diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma. According to an announcement from the U.S. Food and Drug Administration, the updated indication covers the frontline treatment of patients who do not have a known 17p deletion, allowing individuals to access the targeted therapy earlier in their care journey.
The expanded regulatory decision is supported by findings from the randomized BRUIN-CLL-313 clinical trial. Data from the study demonstrated that treatment with pirtobrutinib lowered the relative risk of disease progression or death by 80% when compared against standard chemoimmunotherapy regimens. Specifically, investigators observed a median progression-free survival that was not yet estimable in the pirtobrutinib arm, compared with 33.5 months for patients who received a combination of bendamustine and rituximab. Furthermore, the overall response rate reached 94% among participants taking the targeted medication, contrasted with 81% in the comparator arm.
Clinical investigators note that this broader indication represents a meaningful shift in how physicians can approach initial therapy for these specific blood cancers. Dr. Jennifer Woyach, an investigator from the Ohio State University Comprehensive Cancer Center, highlighted the significance of the findings in a press release issued by drug manufacturer Eli Lilly. Dr. Woyach noted that clinicians can now consider the non-covalent BTK inhibitor when initial treatment becomes necessary, rather than reserving it exclusively for later stages of a patient’s treatment path. Because modern targeted therapies offer high efficacy and tolerability—balanced against individual factors like age and existing health conditions—many individuals diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma may only undergo one or two lines of therapy throughout their lives, making the choice of initial treatment critically important.
Pirtobrutinib initially received accelerated approval from the regulatory agency in 2023 for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The medication has also demonstrated clinical activity in patients experiencing Richter transformation, a notoriously difficult-to-treat complication, and remains the only approved non-covalent BTK inhibitor in the United States. It is also authorized for the care of individuals with previously treated mantle cell lymphoma.
Regarding safety, Dr. Woyach stated that the open-label BRUIN-CLL-313 trial confirmed the drug’s safety and tolerability profile remained consistent with previously established data. The most frequently reported non-laboratory adverse events observed in trial participants receiving pirtobrutinib included upper respiratory tract infections in 27% of patients, rash in 22%, and COVID-19 diagnoses in 21%. Among laboratory abnormalities, decreased neutrophil counts represented the most common grade 3 or 4 event, affecting 26% of patients, while serious adverse events were documented in 28% of individuals.
Official prescribing information for pirtobrutinib includes important warnings and precautions. Patients and healthcare providers must monitor for potential risks including infections, bleeding events, cytopenias, cardiac arrhythmias, secondary primary malignancies, liver toxicity, and embryo-fetal toxicity. Healthcare professionals advise that patients consult their oncology care teams to determine the most appropriate personalized treatment strategy based on individual genetic markers, overall health, and specific diagnostic findings.
Source: MedPage Today
